New treatments for chronic lymphocytic leukemia

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


An enhanced understanding of the important pathways governing chronic lymphocytic leukemia (CLL) cell survival and the critical role played by the microenvironment in the pathogenesis of the disease has brought new opportunities for drug development in CLL. Several new targets have been identified, and novel agents are under intense investigation in clinical trials. Some of these agents are already demonstrating promising anti-CLL activity on their own, whereas others hold promise in combination with existing therapeutic options. As the use of monoclonal antibodies for chemoimmunotherapy becomes standard clinical practice, the future holds promise for concurrent targeting of the tumor cell as well as its microenvironment.

Original languageEnglish (US)
Pages (from-to)353-360
Number of pages8
JournalCurrent oncology reports
Issue number5
StatePublished - Sep 2007

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'New treatments for chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this